Canada offers a comprehensive range of ADHD medications including stimulants, non-stimulants, and various formulations to meet different patient needs.

Stimulant Medications

Methylphenidate-based medications include Ritalin, Concerta, Biphentin, and Foquest. Amphetamine-based options include Vyvanse and Adderall XR. These are first-line treatments for most ADHD patients due to their proven effectiveness.

Non-Stimulant Options

Atomoxetine (Strattera) is a non-stimulant SNRI approved for ADHD. Guanfacine (Intuniv) and clonidine (Catapres) are alpha-2 agonists used off-label, particularly for patients who can’t tolerate stimulants or have co-existing conditions.

Formulation Variety

Canadian patients have access to immediate-release, extended-release, and specialized delivery systems. Choices include chewable tablets, capsules that can be opened and sprinkled, and transdermal patches for consistent delivery.

Access and Regulations

Stimulant medications are controlled substances requiring special prescriptions. Regulations vary by province, but generally involve limits on prescription quantities, required follow-up intervals, and sometimes triplicate prescription forms.

Treatment Approach

Canadian guidelines emphasize comprehensive treatment including medication, behavioral therapy, educational support, and lifestyle modifications. Medication is typically part of a multi-modal approach rather than standalone treatment.

Admin

See all author post